ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

TEVA Teva Pharmaceutical Industries Ltd

13.89
0.64 (4.83%)
27 Apr 2024 - Closed
Delayed by 15 minutes
Name Symbol Market Type
Teva Pharmaceutical Industries Ltd NYSE:TEVA NYSE Depository Receipt
  Price Change % Change Price High Price Low Price Open Price Traded Last Trade
  0.64 4.83% 13.89 13.98 13.31 13.31 10,713,701 01:00:00

Initial Statement of Beneficial Ownership (3)

17/02/2021 9:12pm

Edgar (US Regulatory)


FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Weil Andrew
2. Date of Event Requiring Statement (MM/DD/YYYY)
2/15/2021 

3. Issuer Name and Ticker or Trading Symbol

TEVA PHARMACEUTICAL INDUSTRIES LTD [TEVA]
(Last)        (First)        (Middle)

C/O TEVA PHARMACEUTICAL INDUSTRIES LTD., 5 BASEL STREET
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                          _____ 10% Owner
___X___ Officer (give title below)        _____ Other (specify below)
Chief Accounting Officer /
(Street)

PETACH TIKVA, L3 4951033      

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares

Explanation of Responses:

Remarks:
Remarks: Exhibit List: Exhibit 24 - Power of Attorney
No securities are beneficially owned.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Weil Andrew
C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.
5 BASEL STREET
PETACH TIKVA, L3 4951033


Chief Accounting Officer

Signatures
/s/ Dov Bergwerk as attorney-in-fact for Andrew Weil2/17/2021
**Signature of Reporting PersonDate

1 Year Teva Pharmaceutical Indu... Chart

1 Year Teva Pharmaceutical Indu... Chart

1 Month Teva Pharmaceutical Indu... Chart

1 Month Teva Pharmaceutical Indu... Chart

Your Recent History

Delayed Upgrade Clock